Faron Pharmaceuticals - Innovative medical solutions (Part 2)

The potential €40M funding from the share issue will be sufficient for the period from Q2 2026 to H1 2027. This means that strategic partnerships should be established by H1 next year at the latest, for which further research results can start to arrive in 2026/2027. Otherwise, an additional share issue will be required.

1 Like